title: Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review.
abstract: Cancer and cancer therapy-associated anemia may have an impact on tumor response and overall survival. Additionally, anemia represents an important economic factor. Therefore, therapeutic alternatives such as erythropoietin (EPO) and red blood cell transfusions have to be evaluated systematically. The effectiveness of recombinant human EPO to prevent or alleviate anemia in patients with malignant disease was determined. Randomized controlled trials comparing prophylaxis or treatment of anemia with EPO plus red blood cell transfusion (RBCT) or RBCT only in patients with malignant disease undergoing antineoplastic therapy were included. The endpoints needed for RBCT were hematological response (hemoglobin increase of 2g/dL or hematocrit increase of 6%), tumor response, and overall survival. Medical databases (Cochrane Library, MEDLINE, EMBASE) and conference proceedings were searched (1985-2001). Full-text and abstract publications were included as well as unpublished data. Data extraction and quality assessment were done in duplicate. All authors were contacted to obtain missing data. Out of 33 eligible studies, 27 trials with 3,287 randomized patients were included.
authors.affiliation: Cochrane Hematological Malignancies Group, Department I of Internal Medicine, University of Cologne, Kerpener-Street 9, 50924 Cologne, Germany. julia.bohlius@uni-koeln.de
authors.forename: Julia F
authors.initials: JF
authors.lastname: Bohlius
authors.forename: Simon
authors.initials: S
authors.lastname: Langensiepen
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Guido
authors.initials: G
authors.lastname: Schwarzer
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000517:prevention & control; D016208:Databases, Factual / Q000706:statistics & numerical data; D003663:Decision Trees; D017707:Erythrocyte Transfusion / Q000379:methods; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009369:Neoplasms / Q000150:complications*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins; D014481:United States
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin